225 related articles for article (PubMed ID: 28269771)
1. Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.
Gervaise-Henry C; Watfa G; Albuisson E; Kolodziej A; Dousset B; Olivier JL; Jonveaux TR; Malaplate-Armand C
J Alzheimers Dis; 2017; 57(2):437-445. PubMed ID: 28269771
[TBL] [Abstract][Full Text] [Related]
2. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
3. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
Bali D; Hansson O; Janelidze S
Alzheimers Res Ther; 2024 Feb; 16(1):31. PubMed ID: 38331843
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).
Vanderstichele H; Demeyer L; Janelidze S; Coart E; Stoops E; Mauroo K; Herbst V; François C; Hansson O
Alzheimers Res Ther; 2017 Jun; 9(1):40. PubMed ID: 28587660
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
6. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.
Schoonenboom NS; Mulder C; Vanderstichele H; Van Elk EJ; Kok A; Van Kamp GJ; Scheltens P; Blankenstein MA
Clin Chem; 2005 Jan; 51(1):189-95. PubMed ID: 15539465
[TBL] [Abstract][Full Text] [Related]
7. Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes.
Vanderstichele HM; Janelidze S; Demeyer L; Coart E; Stoops E; Herbst V; Mauroo K; Brix B; Hansson O
J Alzheimers Dis; 2016 May; 53(3):1121-32. PubMed ID: 27258423
[TBL] [Abstract][Full Text] [Related]
8. Towards a unified protocol for handling of CSF before β-amyloid measurements.
Janelidze S; Stomrud E; Brix B; Hansson O
Alzheimers Res Ther; 2019 Jul; 11(1):63. PubMed ID: 31324260
[TBL] [Abstract][Full Text] [Related]
9. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease.
Kurz C; Stöckl L; Schrurs I; Suridjan I; Gürsel SÜ; Bittner T; Jethwa A; Perneczky R
J Neurochem; 2023 Apr; 165(1):95-105. PubMed ID: 36625424
[TBL] [Abstract][Full Text] [Related]
10. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease.
Biscetti L; Salvadori N; Farotti L; Cataldi S; Eusebi P; Paciotti S; Parnetti L
Clin Chim Acta; 2019 Jul; 494():71-73. PubMed ID: 30844364
[TBL] [Abstract][Full Text] [Related]
11. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.
Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O
Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of Aβ40 and Aβ42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease.
Fiorini M; Bongianni M; Benedetti MD; Monaco S; Zanusso G
J Alzheimers Dis; 2018; 66(1):219-227. PubMed ID: 30282368
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
14. Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
Bellomo G; Cataldi S; Paciotti S; Paolini Paoletti F; Chiasserini D; Parnetti L
Alzheimers Res Ther; 2020 Sep; 12(1):121. PubMed ID: 32993776
[TBL] [Abstract][Full Text] [Related]
15. Pre-analytical factors influencing the stability of cerebrospinal fluid proteins.
Simonsen AH; Bahl JM; Danborg PB; Lindstrom V; Larsen SO; Grubb A; Heegaard NH; Waldemar G
J Neurosci Methods; 2013 May; 215(2):234-40. PubMed ID: 23537933
[TBL] [Abstract][Full Text] [Related]
16. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
[TBL] [Abstract][Full Text] [Related]
17. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
[TBL] [Abstract][Full Text] [Related]
18. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.
Fukuyama R; Mizuno T; Mori S; Nakajima K; Fushiki S; Yanagisawa K
Eur Neurol; 2000; 43(3):155-60. PubMed ID: 10765056
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
20. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
